Dmitry V. Shabanov
Research Subjects
Dmitry V. Shabanov has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- A. V. Yurin
Odintsovo Regional Hospital
1 shared publication - Alexander Yuryevich Gorshkov
National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
1 shared publication - Anna V. Strelkova
Microcirculation and Regional HemodynamicsLaboratory, National Medical Research Center for Therapy and Preventive Medicine, Moscow, 101990, Russia
1 shared publication - Ju. E. Lutkovskaya
Yevdokimov Moscow State University of Medicine and Dentistry
1 shared publication - Mikhail Georgievich Chashchin
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
1 shared publication - Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
1 shared publication
Latest Publications
- Open Access
- 20 April 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (3) , 4253
Laboratory markers of complicated coronary atherosclerosis in patients with non-ST-elevation myocardial infarction
Aim. To study the associations between the level of systemic inflammation markers in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and the severity of infarct-related artery (IRA) involvement according to coronary angiography.Material and methods. The data of 236 patients hospitalized with a diagnosis of NSTEMI in the regional vascular center in Odintsovo from April 2021 to February 2023 were analyzed. All patients underwent examinations in accordance with clinical guidelines. Based on laboratory tests, the level of following inflammatory markers was assessed: leukocytes, high-sensitivity C-reactive protein (hsCRP), fibrinogen. During coronary angiography, the IRA involvement was assessed according to American College of Cardiology/American Heart Association classification. The relationship of inflammatory markers with complicated involvement was assessed in a binary logistic regression model.Results. Depending on the severity of the IRA involvement, the patients were divided into 2 following groups: group 1 included 166 patients with complicated IRA involvement (type B-C), group 2 — 70 patients without complicated IRA involvement (type A). Patients in both groups were comparable in terms of troponin I levels upon admission (p>0,05). Inflammatory markers were significantly higher in group 1 (p≲0,05). Fatal outcome was observed in 4,2% (n=7) of cases in group 1 and in 2,9% (n=2) in group 2 (p=0,62). Levels of hsCRP (odds ratio (OR) 1,19) and fibrinogen (OR 7,96) were associated with the probability of type B-C IRA lesion (pConclusion. Patients with NSTEMI and complicated IRA lesions are characterized by elevated levels of systemic inflammation markers. Higher levels of hsCRP and fibrinogen were significantly associated with type B and C lesions.
- 20 April 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (3) , 4253
Open AccessLaboratory markers of complicated coronary atherosclerosis in patients with non-ST-elevation myocardial infarction
Aim. To study the associations between the level of systemic inflammation markers in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and the severity of infarct-related artery (IRA) involvement according to coronary angiography.Material and methods. The data of 236 patients hospitalized with a diagnosis of NSTEMI in the regional vascular center in Odintsovo from April 2021 to February 2023 were analyzed. All patients underwent examinations in accordance with clinical guidelines. Based on laboratory tests, the level of following inflammatory markers was assessed: leukocytes, high-sensitivity C-reactive protein (hsCRP), fibrinogen. During coronary angiography, the IRA involvement was assessed according to American College of Cardiology/American Heart Association classification. The relationship of inflammatory markers with complicated involvement was assessed in a binary logistic regression model.Results. Depending on the severity of the IRA involvement, the patients were divided into 2 following groups: group 1 included 166 patients with complicated IRA involvement (type B-C), group 2 — 70 patients without complicated IRA involvement (type A). Patients in both groups were comparable in terms of troponin I levels upon admission (p>0,05). Inflammatory markers were significantly higher in group 1 (p≲0,05). Fatal outcome was observed in 4,2% (n=7) of cases in group 1 and in 2,9% (n=2) in group 2 (p=0,62). Levels of hsCRP (odds ratio (OR) 1,19) and fibrinogen (OR 7,96) were associated with the probability of type B-C IRA lesion (pConclusion. Patients with NSTEMI and complicated IRA lesions are characterized by elevated levels of systemic inflammation markers. Higher levels of hsCRP and fibrinogen were significantly associated with type B and C lesions.
- Open Access
- 26 June 2021
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 18 (2) , 149-150
Vera Nikolaevna Fedoseeva: in memory of outstanding scientist, teacher, person
On May 12, at the age of 83, a famous Russian scientist in the field of allergology, academician of the Russian Academy of Natural Sciences in biomedical sciences, doctor of biological sciences, professor Vera Nikolaevna Fedoseeva passed away. Vera Nikolaevna was one of the founders of the national, now internationally recognized Association of Allergists and Clinical Immunologists, a student of the founder of Russian allergology, Academician Andrei Dmitrievich Ado.
- 26 June 2021
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 18 (2) , 149-150
Open AccessVera Nikolaevna Fedoseeva: in memory of outstanding scientist, teacher, person
On May 12, at the age of 83, a famous Russian scientist in the field of allergology, academician of the Russian Academy of Natural Sciences in biomedical sciences, doctor of biological sciences, professor Vera Nikolaevna Fedoseeva passed away. Vera Nikolaevna was one of the founders of the national, now internationally recognized Association of Allergists and Clinical Immunologists, a student of the founder of Russian allergology, Academician Andrei Dmitrievich Ado.
- Open Access
- 14 November 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 26-35
Actual antihistamine therapy
The significance of the issues of allergic diseases is not in doubt. It is difficult to find a person who has not suffered at least some Allergy symptom, not everyone develops diseases, but most people face Allergy symptoms. The prevalence of various allergic diseases is increasing every year, currently reaching 30% of the population, and the world health organization predicts it will reach 50% in the next few decades. The most common nosologies are allergic rhinitis, bronchial asthma, atopic dermatitis, urticaria, but there are many other conditions of hypersensitivity. This article addresses the issues of inflammatory reactions in General and specifically allergic inflammation, discusses the main aspects of the pathogenesis of allergic rhinitis and urticaria, and questions of drug therapy for these diseases. Most people are sure that they can take anti-allergic medications for allergies, and most often they are referring to antihistamines. Unfortunately, even some medical specialists lack an understanding of the specifics of antihistamine therapy. some people still believe that there are three or four generations of antihistamines, and patients use drugs not as prescribed by doctors, but on the recommendation of friends or pharmacists. Irrational use of antihistamines leads to a decrease in effectiveness, and it is not uncommon to discredit specific drugs and groups of drugs in General. This article demonstrates the results of various European and Asian studies on the effectiveness and safety of antihistamines and bilastin in particular, as well as their own experience of using antihistamines in practice.
- 14 November 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 26-35
Open AccessActual antihistamine therapy
The significance of the issues of allergic diseases is not in doubt. It is difficult to find a person who has not suffered at least some Allergy symptom, not everyone develops diseases, but most people face Allergy symptoms. The prevalence of various allergic diseases is increasing every year, currently reaching 30% of the population, and the world health organization predicts it will reach 50% in the next few decades. The most common nosologies are allergic rhinitis, bronchial asthma, atopic dermatitis, urticaria, but there are many other conditions of hypersensitivity. This article addresses the issues of inflammatory reactions in General and specifically allergic inflammation, discusses the main aspects of the pathogenesis of allergic rhinitis and urticaria, and questions of drug therapy for these diseases. Most people are sure that they can take anti-allergic medications for allergies, and most often they are referring to antihistamines. Unfortunately, even some medical specialists lack an understanding of the specifics of antihistamine therapy. some people still believe that there are three or four generations of antihistamines, and patients use drugs not as prescribed by doctors, but on the recommendation of friends or pharmacists. Irrational use of antihistamines leads to a decrease in effectiveness, and it is not uncommon to discredit specific drugs and groups of drugs in General. This article demonstrates the results of various European and Asian studies on the effectiveness and safety of antihistamines and bilastin in particular, as well as their own experience of using antihistamines in practice.